Home > Insider Trading > Filing (0001209191-16-146390)

Filing Details

Accession Number:: 0001209191-16-146390
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-10-19 17:51:01
Reporting Period:: 2016-10-17

Filing Date:: 2016-10-19
Accepted Time:: 2016-10-19 17:51:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1423824	Alder Biopharmaceuticals Inc	ALDR	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1604834	James Mark Litton	11804 North Creek Parkway South Bothell WA 98011	Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-10-17	2,000	$27.50	26,000	No	4	S	Indirect	Held in trust for the benefit of Reporting Person's minor child
Common Stock	Disposition	2016-10-17	2,000	$27.50	26,000	No	4	S	Indirect	Held in trust for the benefit of Reporting Person's minor child
Common Stock	Disposition	2016-10-17	2,000	$27.50	26,000	No	4	S	Indirect	Held in trust for the benefit of Reporting Person's minor child

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	Held in trust for the benefit of Reporting Person's minor child
No	4	S	Indirect	Held in trust for the benefit of Reporting Person's minor child
No	4	S	Indirect	Held in trust for the benefit of Reporting Person's minor child

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	99,567	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by three irrevocable trusts administered by an independent trustee for the benefit of Reporting Person's minor children. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $27.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $27.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $27.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4.